-
公开(公告)号：US11810650B2
公开(公告)日：2023-11-07
申请号：US16592070
申请日：2019-10-03
申请人： Gusto Global, LLC
IPC分类号： G06G7/48 , G16B5/00 , A61K35/741 , A61K35/742 , G16B35/20 , G16B35/00 , G16B99/00
CPC分类号： G16B5/00 , A61K35/741 , A61K35/742 , G16B35/00 , G16B35/20 , G16B99/00
摘要： Methods are provided for the rational design of stable communities of microbes for benefiting the health of a host organism, including human and/or animal health. The methods describe design of microbial consortia based on providing and/or complementing key functionalities lacking or underrepresented in the microbiome of an organism having a disorder or disease as compared to healthy subjects. The consortia are designed to possess metabolic interdependencies for improved engrafting, stability and performance of the consortium. Compositions that include the designed microbial consortia are provided for treatment of disorders/diseases involving chronic inflammation, infection, and the combination of chronic inflammation and infection including inflammatory bowel disease and related disorders. The compositions are also broadly applicable for the treatment of neurological, metabolic and oncology-related conditions.
-
公开(公告)号：US20240096440A1
公开(公告)日：2024-03-21
申请号：US18367513
申请日：2023-09-13
申请人： Gusto Global, LLC
IPC分类号： G16B5/00 , A61K35/741 , A61K35/742 , G16B35/00 , G16B35/20
CPC分类号： G16B5/00 , A61K35/741 , A61K35/742 , G16B35/00 , G16B35/20 , G16B99/00
摘要： Methods are provided for the rational design of stable communities of microbes for benefiting the health of a host organism, including human and/or animal health. The methods describe design of microbial consortia based on providing and/or complementing key functionalities lacking or underrepresented in the microbiome of an organism having a disorder or disease as compared to healthy subjects. The consortia are designed to possess metabolic interdependencies for improved engrafting, stability and performance of the consortium. Compositions that include the designed microbial consortia are provided for treatment of disorders/diseases involving chronic inflammation, infection, and the combination of chronic inflammation and infection including inflammatory bowel disease and related disorders. The compositions are also broadly applicable for the treatment of neurological, metabolic and oncology-related conditions.
-
公开(公告)号：US20230381247A1
公开(公告)日：2023-11-30
申请号：US18032745
申请日：2021-10-14
申请人： Gusto Global, LLC
IPC分类号： A61K35/742 , C12N1/20 , A61K45/06 , A61P29/00
CPC分类号： A61K35/742 , C12N1/20 , A61K45/06 , A61P29/00 , C12R2001/145
摘要： Compositions containing live cultures of 11 separately isolated bacterial strains (the bacterial consortium containing all 11 strains designated GUT-108) are provided for treating conditions of systemic inflammation including, to name a few, Inflammatory Bowel Diseases, type-2 diabetes, metabolic syndrome and obesity, and aging-related conditions of chronic inflammation. In a mouse model of chronic immune-mediated colitis, therapeutic application of GUT-108 reversed the established inflammation in the cecum. In addition, the treatment with GUT-108 unexpectedly resulted in restoration of a healthy gut microbiome in the mice containing an abundance of beneficial Clostridium strains not part of GUT-108, and a decrease in abundance of the applied pathogenic Enterobacteriaceae bacteria from 5% to below 0.5%. An eight-fold decrease in the levels of pathogenic Clostridium perfringens was also observed after treatment with GUT-108, indicating the efficacy of GUT-108 in treating inflammation caused by pathogenic species of the Enterobacteriaceae or pathogenic species of Clostridium.
-
公开(公告)号：US20200027524A1
公开(公告)日：2020-01-23
申请号：US16592070
申请日：2019-10-03
申请人： Gusto Global, LLC
IPC分类号： G16B5/00 , A61K35/741 , A61K35/742
摘要： Methods are provided for the rational design of stable communities of microbes for benefiting the health of a host organism, including human and/or animal health. The methods describe design of microbial consortia based on providing and/or complementing key functionalities lacking or underrepresented in the microbiome of an organism having a disorder or disease as compared to healthy subjects. The consortia are designed to possess metabolic interdependencies for improved engrafting, stability and performance of the consortium. Compositions that include the designed microbial consortia are provided for treatment of disorders/diseases involving chronic inflammation, infection, and the combination of chronic inflammation and infection including inflammatory bowel disease and related disorders. The compositions are also broadly applicable for the treatment of neurological, metabolic and oncology-related conditions.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
